The disclosure relates to synthetic oligonucleotides that are unique in that they are RNA molecules that have the capacity to form a hydrogel. Also disclosed are DNA oligonucleotides that encode the RNA oligos so that the oligos can be prepared using in vitro transcription. The disclosure further pertains to pharmaceutical compositions comprising these hydrogels.
1. A synthetic RNA oligonucleotide consisting of the nucleotide sequence of SEQ ID NO: 1, 8, 9, 15 or 16.
2. A synthetic RNA oligonucleotide comprising the nucleotide sequence of SEQ ID NO: 1, 8, 9, 15 or 16.
3. A synthetic RNA oligonucleotide comprising tandem repeats of the nucleotide sequence of SEQ ID NO: 1, 8, 9, 15 or 16.
4. The synthetic oligonucleotide of claim 3 consisting of the nucleotide sequence of SEQ ID NO: 2.
5. The synthetic oligonucleotide of claim 3 comprising the nucleotide sequence of SEQ ID NO: 2.
6. The synthetic oligonucleotide of claim 3 , where said tandem repeats are separated by a linking/intervening nucleotide sequence.
7. A hydrogel comprising the synthetic oligonucleotide of claim 1 .
8. A synthetic oligonucleotide that encodes an RNA of claim 1 .
9. A synthetic oligonucleotide of claim 8 , wherein the oligonucleotide consists of the nucleotide sequence of SEQ ID NO: 3.
10. The synthetic oligonucleotide of claim 8 , wherein the oligonucleotide consists of the nucleotide sequence of SEQ ID NO: 4.
11. A pharmaceutical composition comprising a synthetic oligonucleotide consisting of the nucleotide sequence of SEQ ID NO: 1, 2, 8, 9, 15 or 16.
12. A pharmaceutical composition comprising a hydrogel comprising an oligonucleotide with the nucleotide sequence of SEQ ID NO: 1, 2, 8, 9, 15 or 16.